Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 9/20 | 0.41 |
| ▸ | CES2 | O00748 | 7/20 | 0.41 |
| ▸ | CES1 | P23141 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592388 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TSHRACHECES2CES1 | |
| SCHEMBL7853979 | 0.98 | ALDH1A1 (0.47) | ALDH1A1TSHRACHECES2CES1 | |
| SCHEMBL7853980 | 0.98 | ALDH1A1 (0.47) | ALDH1A1TSHRACHECES2CES1 | |
| SCHEMBL4623907 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRACHECES2CES1 | |
| SCHEMBL4623904 | 0.85 | ALDH1A1 (0.44) | ALDH1A1TSHRACHECES2CES1 | |
| SCHEMBL13237290 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TSHRCYP2C9MAPTKMT2A | |
| SCHEMBL4625277 | 0.80 | CES2 (0.37) | ALDH1A1ACHECES2CES1MAPT | |
| SCHEMBL4625272 | 0.80 | CES2 (0.37) | ALDH1A1ACHECES2CES1MAPT | |
| SCHEMBL7715361 | 0.80 | CES2 (0.37) | ALDH1A1ACHECES2CES1MAPT | |
| SCHEMBL13237291 | 0.80 | TSHR (0.45) | TSHRCES2CES1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-2566866-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES USEFUL AS PKC-THETA INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011139273-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES USEFUL AS PKC-THETA INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-1067121-B1 | 5-Aminopyrazole-4-carboxylate derivative and process for preparing the same | MITSUI CHEMICALS INC (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-6235911-B1 | 5-aminopyrazole-4-carboxylate derivative and process for preparing the same | MITSUI CHEMICALS, INC. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-1067121-A2 | 5-Aminopyrazole-4-carboxylate derivative and process for preparing the same | Mitsui Chemicals, Inc. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | MAP4K5, MAP4K4, MAP4K2 | ALDH1A1 2643/4885TSHR 3959/4885ACHE 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.